Outcomes associated with conventional versus lipid-based formulations of amphotericin B in propensity-matched groups

BACKGROUND: Lipid-based formulations of amphotericin B (LF-AMB) are indicated for treatment of invasive fungal infections in patients intolerant to conventional amphotericin B (CAB) or with refractory infections. Physicians still may choose to administer CAB to such patients. We described the use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Rebecca S, Chaudhari, Paresh, Hays, Harlen D, Taylor, Robert J, Nathanson, Brian H, Bozzette, Samuel A, Horn, David L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810329/
https://www.ncbi.nlm.nih.gov/pubmed/24187506
http://dx.doi.org/10.2147/CEOR.S46834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810329/
https://www.ncbi.nlm.nih.gov/pubmed/24187506
http://dx.doi.org/10.2147/CEOR.S46834

Ejemplares similares